NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

The UK government is considering raising the amount the National Health Service (NHS) pays pharmaceutical companies for medicines by up to 25%. This move is part of efforts to resolve a standoff with the industry and the Trump administration. The proposed changes include modifying the cost-effectiveness thresholds used to assess new medications for use in the NHS. This is seen as a way to end the ongoing dispute with drugmakers, which has been cited as a reason for firms cutting their investments in the UK. The negotiations have been intensive, with the Labour party also involved in developing fresh proposals to address the issue. The goal is to find a solution that works for both the NHS and the pharmaceutical industry, ensuring continued access to necessary medications for patients while maintaining a sustainable business environment for drug companies.